9 completed, 7 active not recruiting, 3 terminated, 2 recruiting. 16 Phase 2, 10 Phase 1, 1 Early Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 16 | Completed 6, Active not recruiting 4, Terminated 3, Recruiting 2, Unknown 1 |
| Phase 1 | 10 | Completed 6, Active not recruiting 2, Terminated 2 |
| Early Phase 1 | 1 | Active not recruiting 1 |
Follow Multiple Myeloma Research Consortium: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Horizon Two: HR NDMM (MMRC-100) Bispecific Monoclonal Antibody and Triplet Therapy, Monoclonal Antibody with Stem Cell Transplant - High Risk Newly Diagnosed Multiple Myeloma | Phase 2 | Recruiting | Multiple Myeloma Research Consortium | 300 | 2026-04-30 | 2026-10-02 |
| MMRC Horizon One: RRMM (MMRC-099) Teclistamab Monotherapy, Teclistamab - Relapse Multiple Myeloma, Refractory Multiple Myeloma | Phase 2 | Active not recruiting | Multiple Myeloma Research Consortium | 300 | 2024-11-17 | 2026-06-05 |
| Iberdomide and Daratumumab as Maintenance Therapy After an Autologous Stem Cell Transplant for Multiple Myeloma Iberdomide, Daratumumab/rHuPH20 Co-formulation - Multiple Myeloma | Phase 2 | Recruiting | Barbara Ann Karmanos Cancer Institute | 60 | 2023-12-21 | 2026-06-26 |
| A Study of Iberdomide (CC-220) in Combination With Elotuzumab and Dexamethasone for Relapsed/Refractory Multiple Myeloma Iberdomide, Elotuzumab, Dexamethasone - Multiple Myeloma | Early Phase 1 | Active not recruiting | Icahn School of Medicine at Mount Sinai | 7 | 2023-02-06 | 2026-01-02 |
| Immuno-Oncology Drugs Elotuzumab, Anti-LAG-3 and Anti-TIGIT Elotuzumab, pomalidomide, dexamethasone, Anti-LAG-3, Anti-LAG-3 + Pomalidimide + Dexamethasone - Multiple Myeloma, Relapsed Refractory Multiple Myeloma | Phase 1 / Phase 2 | Terminated | Multiple Myeloma Research Consortium | 14 | 2020-07-10 | 2025-02-14 |
| Myeloma-Developing Regimens Using Genomics (MyDRUG) Abemaciclib, dexamethasone, ixazomib, pomalidomide, Enasidenib, dexamethasone, ixazomib, pomalidomide, Cobimetinib, dexamethasone, ixazomib, pomalidomide - Relapsed Refractory Multiple Myeloma | Phase 1 / Phase 2 | Completed | Multiple Myeloma Research Consortium | 103 | 2019-04-01 | 2025-02-14 |
| LCI-HEM-MYE-CRD-004 (MMRC-073 CARJAK): Study of CRD for Carfilzomib-Refractory Multiple Myeloma Carfilzomib, Ruxolitinib, Dexamethasone - Multiple Myeloma | Phase 1 / Phase 2 | Completed | Wake Forest University Health Sciences | 12 | 2019-01-03 | 2025-01-13 |
| Phase II Study of the CD38 Antibody Daratumumab in Patients With High-Risk MGUS and Low-Risk Smoldering Multiple Myeloma Daratumumab - Monoclonal Gammopathy, Smoldering Multiple Myeloma | Phase 2 | Active not recruiting | Dana-Farber Cancer Institute | 42 | 2017-11-24 | 2026-03-27 |
| Lenalidomide, Dexamethasone, and Elotuzumab With or Without Cyclophosphamide in Treating Patients With Relapsed Primary Amyloidosis Cyclophosphamide, Dexamethasone, Elotuzumab - Recurrent Primary Amyloidosis | Phase 2 | Unknown | Barbara Ann Karmanos Cancer Institute | 53 | 2017-08-25 | 2023-01-25 |
| A Study of Dabrafenib and/or Trametinib in Patients With Relapsed and/or Refractory Multiple Myeloma Dabrafenib, Trametinib - Multiple Myeloma | Phase 1 | Active not recruiting | Massachusetts General Hospital | 30 | 2017-06-21 | 2026-07-31 |
| Testing JNJ-42756493 In Combination With Dexamethasone in Multiple Myeloma That Came Back After a Period of Improvement JNJ-42756493, Dexamethasone - Multiple Myeloma, Relapsed/Refractory | Phase 2 | Terminated | University Health Network, Toronto | 20 | 2017-06-13 | 2020-09-17 |
| A Phase II Trial If Nivolumab, Lenalidomide and Dexamethasone in High Risk Smoldering Myeloma Nivolumab, Lenalidomide, Dexamethasone - Smoldering Multiple Myeloma | Phase 2 | Completed | Dana-Farber Cancer Institute | 8 | 2016-10-20 | 2023-06-13 |
| Ixazomib and Dexamethasone Versus Ixazomib, Dexamethasone and Lenalidomide, Randomized With NFKB2 Rearrangement Dexamethasone, Ixazomib, Lenalidomide - Recurrent Plasma Cell Myeloma, Refractory Plasma Cell Myeloma | Phase 2 | Completed | Emory University | 70 | 2016-09-01 | 2025-06-26 |
| A Study of Elotuzumab With Pomalidomide, Bortezomib, and Dexamethasone in Relapsed Multiple Myeloma Elotuzumab, Pomalidomide, Bortezomib - Multiple Myeloma | Phase 2 | Active not recruiting | Massachusetts General Hospital | 52 | 2016-06-21 | 2026-01-22 |
| Phase II Study of IRD (Ixazomib, Lenalidomide, Dexamethasone) Post Autologous Stem Cell Transplantation Followed by Maintenance Ixazomib or Lenalidomide for Multiple Myeloma Ixazomib, Lenalidomide, Dexamethasone - Multiple Myeloma | Phase 2 | Active not recruiting | Washington University School of Medicine | 236 | 2015-01-20 | 2025-11-10 |
| E-PRISM: Phase II Trial of Elotuzumab Lenalidomide and Dexamethasone in High-Risk Smoldering Multiple Myeloma Elotuzumab, Lenalidomide, Dexamethasone - Smoldering Myeloma, Smoldering Multiple Myeloma | Phase 2 | Completed | Dana-Farber Cancer Institute | 51 | 2014-12-11 | 2023-06-09 |
| A Trial of ASP7487 (OSI-906) in Combination With Bortezomib for the Treatment of Relapsed Multiple Myeloma ASP7487, Velcade, Dexamethasone - Multiple Myeloma | Phase 1 / Phase 2 | Terminated | University Health Network, Toronto | 19 | 2012-09-01 | 2018-09-13 |
| Sotatercept (ACE-011) With Lenalidomide or Pomalidomide and Dexamethasone in Relapsed/Refractory Multiple Myeloma ACE-011, Lenalidomide, Dexamethasone - Multiple Myeloma | Phase 1 | Active not recruiting | Massachusetts General Hospital | 33 | 2012-05-01 | 2026-06-25 |
| Study to Determine the Maximum Tolerated Dose for the Combination of Pomalidomide, Bortezomib and Low-Dose Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma Pomalidomide, Bortezomib, Dexamethasone - Multiple Myeloma | Phase 1 | Completed | Celgene | 34 | 2012-02-15 | 2020-04-07 |
| A Phase I Study of Ganetespib +/- Bortezomib in Patients With Relapsed and/or Refractory Multiple Myeloma Ganetespib, Bortezomib, Dexamethasone - Multiple Myeloma | Phase 1 | Completed | Emory University | 8 | 2012-01-01 | 2015-10-12 |
Showing 20 of 22. Sign in to see all of them.
Multiple Myeloma (17) · Recurrence (6) · Neoplasms, Plasma Cell (3) · Smoldering Multiple Myeloma (3) · Paraproteinemias (2) · Blood Protein Disorders (1) · Hematologic Diseases (1) · Hemorrhagic Disorders (1) · Hemostatic Disorders (1) · Immune System Diseases (1) · Immunoglobulin Light-chain Amyloidosis (1) · Immunoproliferative Disorders (1) · Lymphoproliferative Disorders (1) · Neoplasms (1) · Neoplasms by Histologic Type (1)
Dexamethasone (16) · Calcium Dobesilate (9) · Lenalidomide (6) · Bortezomib (5) · elotuzumab (5) · pomalidomide (5) · daratumumab (3) · ixazomib (3) · carfilzomib (2) · erdafitinib (2) · iberdomide (2) · ACE-011 (1) · Antibodies, Bispecific (1) · Antibodies, Monoclonal (1) · Cyclophosphamide (1)
United States (21) · Canada (2)
Irene Ghobrial, MD (2) · Jeffrey Zonder, M.D. (2) · Amine Bensmaine, MD (1) · Andrew J Yee, MD (1) · Andrew J. Yee, MD (1) · Cesar Rodriguez, MD (1) · Hearn J Cho, M.D., Ph.D. (1) · Hearn J Cho, MD, PhD (1) · Hearn J. Cho, M.D., Ph.D. (1) · Hearn Jay Cho, MD, PhD (1) · Irene M. Ghobrial, MD (1) · Jonathan Kaufman, MD (1) · Leon Bernal-Mizrachi, MD (1) · Madhav V. Dhodapkar, M.D. (1) · Noopur S Raje, MD (1)
PMID 23417027, PMID 30610196, PMID 35027656, PMID 36639200, PMID 38652812, PMID 39187595, PMID 39626297
P30CA022453 (1), P30CA138292 (1)